10. Corticosteroids in Septic Shock & Critical Illness

Quick Recap

Cross-cutting pharmacotherapy protocol — companion to Septic Shock (revised, Infectious Diseases System), which references corticosteroids briefly for vasopressor-refractory shock; this protocol provides the full evidentiary basis for that recommendation, including the genuine, still-not-fully-resolved discordance between the two largest, most rigorous trials on the topic.

1. Definition

Critical Illness-Related Corticosteroid Insufficiency (CIRCI): a state of systemic inflammation involving dysregulation of the hypothalamic-pituitary-adrenal axis, altered cortisol metabolism, and tissue resistance to corticosteroids — associated with sepsis/septic shock, ARDS, and severe pneumonia among other critical illnesses. This concept, and specifically the older practice of diagnosing it via a cosyntropin (ACTH) stimulation test to identify "relative adrenal insufficiency," has been substantially de-emphasized in current practice (Section 22/23) in favor of empiric, response-based dosing in appropriate clinical contexts rather than a formal diagnostic test-driven approach.

Adjunctive corticosteroid therapy in septic shock: low-to-moderate dose hydrocortisone (± fludrocortisone), given not as a diagnosis-driven replacement therapy for confirmed adrenal insufficiency, but as an adjunctive treatment for vasopressor-refractory septic shock specifically — the current indication framework (cross-reference Septic Shock protocol) is based on the clinical scenario (persistent vasopressor dependence despite adequate fluid resuscitation), not a biochemical adrenal insufficiency diagnosis.

2. Pathophysiology

Septic shock produces a complex, incompletely understood state of relative glucocorticoid and mineralocorticoid insufficiency/resistance: NF-κB-mediated down-regulation of vascular mineralocorticoid receptors has been demonstrated experimentally, and this down-regulation is mechanistically linked to impaired vascular contractile response to catecholamines — providing the specific biological rationale for adding fludrocortisone (a mineralocorticoid-receptor agonist) to hydrocortisone, rather than assuming glucocorticoid replacement alone addresses the full physiological deficit. In experimental endotoxic shock models, treatment with a mineralocorticoid-receptor agonist restored alpha-1-adrenoceptor expression, improved contractile response to phenylephrine, and improved survival — this mechanistic distinction between glucocorticoid-only and combined glucocorticoid-plus-mineralocorticoid therapy is central to understanding why the two largest trials (Section 11) used different regimens and arrived at different conclusions.

3. Immediate Stabilization (ABCDE) — Corticosteroid Initiation as Part of Circulation Management

Not a standalone acute stabilization scenario; corticosteroid initiation sits within the Circulation component of septic shock management (cross-reference Septic Shock and Vasopressor & Inotrope Selection & Titration protocols):

Checklist:

4. Focused History

• Duration and severity of vasopressor requirement (informs "refractory" classification and, per APROCCHSS's stricter enrollment criteria, may inform which patients are most likely to benefit — Section 22)
• Underlying source of septic shock (a subgroup analysis has specifically examined community-acquired pneumonia-related septic shock — Section 22)
• Prior corticosteroid exposure (relevant to both baseline HPA axis status and trial-exclusion-criteria-informed practice, since most major trials excluded patients with recent corticosteroid therapy)
• Diabetes/glycemic control status (relevant to anticipating the hyperglycemia adverse effect)

5. Comprehensive System-wise Examination

Not a primary examination-driven protocol; relevant findings are the same vasopressor-refractory shock picture already assessed under Septic Shock and Vasopressor & Inotrope Selection & Titration protocols.

6. Syndrome Identification — Reframed as Indication Classification

• Vasopressor-refractory septic shock: the primary, evidence-supported indication for adjunctive corticosteroids (Section 11)
• Septic shock, not yet vasopressor-refractory: corticosteroids not indicated at this stage per current evidence — reserve for refractory status, not as a routine early addition
• ARDS with an appropriate indication (cross-reference ARDS protocol, Respiratory System, for the ARDS-specific corticosteroid evidence, which is distinct from the septic-shock-specific evidence detailed here)
• Severe COVID-19 pneumonia with hypoxemia: a well-established, distinct corticosteroid indication (RECOVERY trial, Section 11) with its own separate evidence base from the septic shock literature

7. Differential Diagnosis — Not a Traditional Differential

Cross-reference Septic Shock protocol for the differential of refractory hypotension itself; this protocol's relevant "differential" consideration is whether the clinical picture genuinely represents vasopressor-refractory shock warranting corticosteroid consideration, versus an inadequately treated source, undertreated volume status, or inadequate vasopressor titration that should be addressed first per standard escalation principles.

8. Severity/Risk Assessment

Vasopressor dose/duration as the practical severity trigger: current practice reserves corticosteroids for patients with a demonstrated vasopressor requirement despite adequate fluid resuscitation and vasopressor escalation, rather than a fixed biochemical or scoring threshold — this is a clinical judgment call informed by the trial enrollment criteria (Section 22 table) more than a single validated severity score specific to this decision.

Cosyntropin stimulation test: historically used to identify "relative adrenal insufficiency" and guide the corticosteroid decision, but current guidance explicitly recommends against routine use of this test to guide treatment — it does not reliably predict which patients will benefit from corticosteroid therapy, and current practice has moved toward empiric, clinical-scenario-based dosing instead.

9. Investigations

Immediate bedside: not required specifically for the corticosteroid decision itself, beyond standard septic shock monitoring

Routine labs: glucose monitoring intensified once corticosteroids are initiated, given hyperglycemia as the most consistently reported adverse effect across ADRENAL, APROCCHSS, and other major trials

Not indicated: routine cosyntropin stimulation testing to guide the treatment decision (Section 8)

10. Point-of-Care Ultrasound — Not Applicable

11. Evidence-Based Management

The Central Tension — ADRENAL vs. APROCCHSS

Both trials were published in 2018 in the same journal (NEJM), both examined corticosteroids in septic shock with mortality as a primary/key endpoint, and they reached different conclusions — this is a genuine, still-relevant discordance worth understanding in detail rather than simply picking one trial's answer:

• ADRENAL trial (Venkatesh et al., NEJM 2018, n=3,800, largest trial in this space): hydrocortisone 200 mg/day by continuous IV infusion for 7 days vs. placebo, in mechanically ventilated septic shock patients — no significant 90-day mortality benefit, but faster shock reversal, shorter duration of mechanical ventilation, and fewer blood transfusions required, with hyperglycemia as the main adverse effect
• APROCCHSS trial (Annane et al., NEJM 2018, n=1,241): hydrocortisone 50 mg IV bolus every 6 hours (200 mg/day in divided bolus doses, not continuous infusion) plus fludrocortisone 50 mcg enterally once daily, for 7 days, vs. placebo, in patients with persistent septic shock not improving after the initial 6-hour resuscitation bundle — significant 90-day mortality reduction, faster shock reversal, more vasopressor- and organ-failure-free days
• Why they likely differ — patient population and regimen differences, not necessarily a true contradiction: the APROCCHSS cohort was sicker (higher vasopressor requirement at enrollment) than the ADRENAL cohort, and used bolus dosing plus fludrocortisone rather than continuous infusion without fludrocortisone — both the patient selection (sicker, more clearly refractory population) and the regimen (added mineralocorticoid effect) differences offer plausible explanations for the discordant mortality findings, though neither has been definitively proven as the explanatory factor
• Earlier trials for context: CORTICUS (2008) found no mortality benefit and specifically raised concerns about adrenal insufficiency testing/targeting as a flawed paradigm; the original Annane 2002 (Ger-Inf-05) trial had suggested a mortality benefit with low-dose hydrocortisone plus fludrocortisone in a more severely ill population, foreshadowing APROCCHSS's later, larger confirmation of a similar regimen; HYPRESS (2016) found no benefit but was underpowered

Current Practice Synthesis

• Reserve corticosteroids for vasopressor-refractory septic shock — not for septic shock broadly or early in the resuscitation course
• Hydrocortisone 200 mg/day (either as continuous infusion per ADRENAL or as 50 mg IV bolus q6h per APROCCHSS — current guidance does not strongly favor one administration method over the other, though the trials themselves used different approaches) is the standard regimen
• The fludrocortisone question remains genuinely unresolved in routine practice: despite APROCCHSS's positive mortality finding with the combination regimen, an international survey found 79% of clinicians do not prescribe fludrocortisone for septic shock, and current major guidelines (cross-reference Septic Shock protocol) generally do not make a strong recommendation specifically for fludrocortisone addition — this represents a genuine gap between one major trial's positive finding and actual widespread practice, not a case where the evidence was simply not adopted due to oversight
• Recent, more granular evidence continues to explore fludrocortisone specifically: a 2024 subgroup analysis of APROCCHSS examined community-acquired-pneumonia-related septic shock specifically, and a 2024 phase II trial examined the fludrocortisone dose-response relationship directly — both reflect ongoing efforts to refine understanding of the fludrocortisone-specific contribution, which remains less settled than the hydrocortisone-alone evidence base
• Cosyntropin stimulation testing should NOT be used to guide the treatment decision — current guidance and trial evidence do not support this test as a useful gatekeeping step; treatment should be based on the clinical scenario (vasopressor-refractory shock) rather than a biochemical "relative adrenal insufficiency" diagnosis

Distinct Indication — Severe COVID-19/Hypoxemic Respiratory Failure

• RECOVERY trial (dexamethasone in COVID-19): established dexamethasone 6 mg daily for up to 10 days as beneficial specifically in hypoxemic COVID-19 patients requiring supplemental oxygen or ventilation — this is a distinct evidence base and distinct indication from the septic-shock-specific hydrocortisone/fludrocortisone literature above, and should not be conflated with it; cross-reference the relevant Respiratory System/Infectious Diseases System protocols for COVID-19/severe viral pneumonia-specific management

ARDS-Specific Corticosteroid Evidence

• A separate evidence base exists specifically for corticosteroids in ARDS (distinct from the septic-shock indication addressed here) — cross-reference the ARDS protocol (Respiratory System) for that specific literature, which should not be assumed to be interchangeable with the septic-shock-specific evidence in this protocol despite some patient overlap between the two conditions

12. Organ Support

Interacts directly with Vasopressor & Inotrope Selection & Titration protocol — the corticosteroid decision is downstream of confirming genuine vasopressor-refractory status per that protocol's escalation framework, not a parallel or independent decision.

13. Disease-Specific Therapy

• Hydrocortisone 200 mg/day, either as continuous IV infusion (ADRENAL regimen) or 50 mg IV bolus every 6 hours (APROCCHSS regimen), for vasopressor-refractory septic shock; typical duration 7 days
• Fludrocortisone 50 mcg enterally once daily, added to hydrocortisone specifically per the APROCCHSS regimen — genuinely optional/unsettled in current practice (Section 11) rather than a clear standard addition
• Dexamethasone 6 mg daily for up to 10 days — the distinct, well-established regimen specifically for hypoxemic COVID-19 (RECOVERY trial), not interchangeable with the septic-shock-specific hydrocortisone regimens above

14. Consultation Matrix

15. Monitoring Framework

• Clinical: vasopressor requirement trend as the primary marker of treatment response
• Laboratory: glucose monitoring intensified (cross-reference Glycemic Control in Critical Illness protocol — target remains 140–180 mg/dL, not tighter, even with the added hyperglycemic stimulus of corticosteroid therapy)
• Escalation triggers: not applicable in the traditional sense; the relevant reassessment is whether ongoing corticosteroid therapy remains indicated as vasopressor requirement resolves

16. ICU Bundle Checklist

17. Complications

Early:

• Hyperglycemia — the most consistently reported adverse effect across all major trials
• Superinfection risk (monitored as a safety endpoint in APROCCHSS and other trials, though not found to be a major differentiating safety signal)

Late:

• HPA axis suppression with prolonged or repeated corticosteroid courses (relevant to taper planning, though the standard ~7-day course in the major trials was generally well tolerated without a formal taper requirement in most protocols)

Prevention: appropriate indication restriction to vasopressor-refractory shock, intensified glucose monitoring during therapy

Rescue: standard hyperglycemia management per Glycemic Control in Critical Illness protocol; standard infection management if superinfection is suspected

18. Escalation & De-escalation

Escalation: persistent vasopressor-refractory shock despite adequate first-line management (fluids, vasopressors per Vasopressor & Inotrope Selection & Titration protocol) → corticosteroid initiation is the escalation step itself in this context, not a trigger for further escalation beyond it in most cases.

De-escalation: resolving vasopressor requirement → corticosteroid course typically completed at the planned duration (~7 days) rather than titrated day-to-day against vasopressor status in most trial protocols; taper practices vary by institution.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference Septic Shock and ICU Discharge Criteria & Step-Down protocols; corticosteroid-specific consideration at discharge is limited to ensuring the course is completed or an appropriate taper plan is communicated if ongoing.

20. Documentation & Medicolegal Checklist

• Vasopressor-refractory status documented as the indication for corticosteroid initiation
• Regimen selected (continuous infusion vs. divided bolus, fludrocortisone addition or not) and rationale documented
• Glucose monitoring intensification documented
• Course duration and any taper plan documented

21. Key Guidelines

• Current Surviving Sepsis Campaign guidance (cross-reference Septic Shock and Sepsis Bundles & Source Control protocols, incorporating 2026 SSC updates): reserves hydrocortisone for vasopressor-dependent septic shock despite adequate fluid resuscitation — does not make a strong, universal recommendation specifically for fludrocortisone addition, consistent with the genuinely unsettled practice pattern described in Section 11
• RECOVERY trial guidance: established, distinct dexamethasone recommendation for hypoxemic COVID-19, separate from the septic-shock-specific guidance above

22. Landmark Trials

23. Controversies

• The ADRENAL-vs-APROCCHSS discordance remains genuinely, not just historically, unresolved — both are large, well-conducted, contemporaneous RCTs published in the same journal in the same year reaching different conclusions on mortality; the population-severity and regimen (fludrocortisone, bolus vs. infusion) differences are the leading explanations but have not been definitively isolated as the causal factor through a dedicated head-to-head trial. Clinicians should present this as genuine, still-live scientific disagreement rather than implying one trial has been "proven right" and the other "explained away."
• Fludrocortisone's practice-evidence gap is striking and worth explicit attention: despite APROCCHSS's positive mortality finding for the combination regimen, 79% of surveyed clinicians do not prescribe fludrocortisone — this is a substantial, documented gap between one major trial's result and actual practice, distinct from the more common pattern in this library of practice lagging behind a recently updated guideline (e.g., the REVISE trial for stress ulcer prophylaxis); here, practice has not shifted despite the relevant evidence being several years old, suggesting genuine, ongoing clinical skepticism about the fludrocortisone-specific contribution rather than simple lag.
• Abandonment of cosyntropin-stimulation-test-guided treatment: while now well-established as not useful for guiding the treatment decision, this represents a meaningful historical shift in practice paradigm (from a diagnostic-test-driven model to an empiric, clinical-scenario-driven model) that some clinicians trained in the earlier paradigm may not have fully incorporated into current practice.
• Optimal regimen (continuous infusion vs. bolus dosing, fludrocortisone or not) remains genuinely unstandardized: current guidance does not strongly mandate one specific regimen over another, reflecting the underlying discordant trial evidence rather than a settled single "correct" protocol.

24. References

1. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-871.
2. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
3. Keh D, Trips E, Marx G, et al; SepNet-Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;316(17):1775-1785.
4. Venkatesh B, Finfer S, Cohen J, et al; ADRENAL Trial Investigators. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808.
5. Annane D, Renault A, Brun-Buisson C, et al; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock (APROCCHSS). N Engl J Med. 2018;378(9):809-818.
6. Heming N, Renault A, Kuperminc E, et al. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med. 2024;12:366-374.
7. Walsham J, Hammond N, Blumenthal A, et al. Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial. Intensive Care Med. 2024.
8. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704.
9. Steroids in the acutely ill: evolving recommendations and practice. Cleve Clin J Med. 2022;89(9):505-512.
10. The Washington Manual of Critical Care, 4th ed. 2025 — sepsis and adjunctive therapy chapters.
11. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant corticosteroid content.